You are here:

SMC Minutes - Tuesday 04 October 2011

Minutes of the SMC Meeting
held on Tuesday 04 October 2011
Healthcare Improvement Scotland, Delta House, 50 West Nile Street, Glasgow, G1 2NP

Present: Ms Angela Timoney (Chairman), Ms Sandra Auld, Dr Keith Brown, Professor Scott Bryson, Dr Jennifer Burns, Mrs Helen Cadden, Mrs Alison Campbell, Mr Dave Carson, Ms Sara Davies, Dr John Gemmill, Dr Barclay Goudie, Dr Jacqui Howes, Dr Jan Jones, Dr Simon Maxwell, Dr Frances Macdonald, Dr John McElhinney, Mrs Margo McGurk, Dr James McLay, Dr Paul McNamee, Ms Aileen Muir, Mrs Anne Murray, Dr Mercia Page, Dr Robert Peel, Mr Michael Pratt, Professor Colin Suckling,Dr Andrew Walker

In Attendance: Ms Melanie Barnes, Mrs Corinne Booth, Mrs Susan Downie, Ms Ana Garcia-Cebrian, Mr Scott Hill, Mrs Kirsty Macfarlane, Mrs Linda McGlynn, Mr Mike McMahon, Mrs Anne Lee, Mrs Sharon Pfleger, Ms Alex Robertson, Mrs Catherine Tait, Mr Alastair Thorburn, Ms Janice Watt

Apologies: Mrs Laura Ace, Professor James Barbour, Ms Ailsa Brown, Mr Colin Brown, Mr Robert Calderwood, Dr Dominic Culligan, Dr David Dunlop, Mr Stephen Ferguson, Dr Jonathan Fox, Professor Stephen Lawrie, Dr Chris Lush, Ms Veronica Moffat, Dr Alan MacDonald, Mrs Sandra McNaughton, Ms Rosie Murray, Professor Dilip Nathwani, Dr Brian Robson, Mrs Maureen Stark, Dr Sarah Taylor

1. Welcome and Apologies for Absence

1.1 The Chairman welcomed members to the meeting and apologies for absence were noted. 

1.2 A welcome was extended to:

New Staff Members

Mr Scott Hill, Principal Pharmacist, for Emergency Planning at Scottish Government. He has joined the SMC pharmacy team on a part time basis from October 2011.

Mrs Kirsty Macfarlane, Principal Pharmacist, has joined the SMC pharmacy team on a part time basis from October 2011.

NDC Presenters

  • Mr Mike McMahon (Mrs Sharon Pfleger – shadowing)
  • Mr Alastair Thorburn
  • Ms Ana Garcia-Cebrian
  • Ms Janice Watt

2. Declarations of Interest

2.1 The Chairman reminded members to declare interests in the products to be discussed and the comparator drugs as noted on the assessment reports.

3. Minutes of the Previous Meeting (06 September 2011)

3.1 The minutes of the SMC meeting held on 06 September 2011 were accepted as an accurate record of the meeting.

4 Matters Arising

Full Submissions

4.1 rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor®)  AstraZeneca UK  SMC No. (725/11) 

The SMC advice for rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor®), for the treatment of prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event as an adjunct to correction of other risk factors, will be published on the SMC website on Monday, 10 October 2011.

4.2 eribulin 0.44mg/mL solution for injection (Halaven®)  Eisai Ltd  SMC No. (726/11)

The SMC advice for eribulin 0.44mg/mL solution for injection (Halaven®), for treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease.  Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments will be published on the SMC website on Monday, 10 October 2011.

4.3 vardenafil, 10mg orodispersible tablet (Levitra®)  Bayer Healthcare  SMC No. (727/11) 

The SMC advice for vardenafil, 10mg orodispersible tablet (Levitra®), for the treatment of erectile dysfunction (ED) in adult men.  ED is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.  In order for vardenafil to be effective, sexual stimulation is required will be published on the SMC website on Monday, 10 October 2011.

4.4 fluorouracil 0.5% / salicylic acid 10% cutaneous solution (Actikerall®)  Almirall S.A.  SMC No. (728/11)

The SMC advice for fluorouracil 0.5% / salicylic acid 10% cutaneous solution, the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) in immunocompetent adult patients, will be published on the SMC website on Monday, 10 October 2011.

4.5 boceprevir 200mg capsule (Victrelis®) Treatment experienced patients  Merck, Sharpe and Dohme Ltd  SMC No. (722/11)

The SMC advice for boceprevir 200mg capsule (Victrelis®), treatment experienced patients, of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who have failed previous therapy, will be published on the SMC website on Monday, 10 October 2011.

4.6 boceprevir 200mg capsule (Victrelis®)  Treatment naïve patients Merck Sharpe and Dohme Ltd  SMC No. (723/11)

The SMC advice for boceprevir 200mg capsule (Victrelis®), treatment naïve patients of chronic hepatitis C (HCV) genotype 1 infection, in combination with peginterferon and ribavirin, in adult patients with compensated liver disease who are previously untreated, will be published on the SMC website on Monday, 10 October 2011.

Abbreviated Submissions

4.7 botulinum toxin type A, 50 and 100 LD50 units powder for solution for injection (Xeomin®)  Merz Pharma UK Ltd  SMC No. (731/11)

The SMC advice for botulinum toxin type A, 50 and 100 LD50 units powder for solution for injection (Xeomin®), for treatment of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults, will be published on the SMC website on Monday, 10 October 2011.

Non Submissions

4.8 infliximab (Remicade)  Merck Sharp & Dohme Ltd  SMC No. (739/11)

The SMC advice for infliximab (Remicade) for the treatment of moderately active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies, will be published on the SMC website on Monday, 10 October 2011.

4.9  bromfenac (Yellox)  Bausch & Lomb  SMC No. (740/11)

The SMC advice for bromfenac (Yellox) for the treatment of postoperative ocular inflammation following cataract extraction in adults, will be published on the SMC website on Monday, 10 October 2011.

4.10 quetiapine prolonged release (Seroquel XL)  AstraZeneca  SMC No. (744/11)

The SMC advice for quetiapine prolonged release (Seroquel XL) for add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy, will be published on the SMC website on Monday, 10 October 2011.

4.11 conestat alfa (Ruconest)  Swedish Orphan Biovitrum Ltd  SMC No. (745/11)

The SMC advice for conestat alfa (Ruconest) for the treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency, will be published on the SMC website on Monday, 10 October 2011.

Deferred Advice

4.12 Nothing to report.

Amended Advice

4.13 vardenafil, 10mg orodispersible tablet (Levitra®)  Bayer Healthcare SMC No. (727/11)

Vardenafil (Levitra®), for the treatment of erectile dysfunction (ED) in adult men, was reviewed by SMC in September 2011. Following comments from the manufacturer a change has been made to the wording of the ‘Additional Information – budget impact’.  Revised advice will be reissued to NHSBoards and ADTCs on Friday 04 October 2011 and  will be published on the SMC website on Monday 10 October, 2011.

5. Appeals Update

5.1 Nothing to report.

6. Patient and Public Involvement Group (PAPIG)

6.1 PAPIG Update

Mrs Anne Murray advised that PAPIG are due to meet after SMC meeting today.

7. New Drugs Committee: Chairman’s Report

7.1 Nothing to report.

8. Chairman’s Business

8.1 Secure Website for Distributing NDC & SMC Meeting Papers

The two month pilot for web-enabled access to NDC and SMC meeting paperwork is complete.  Thank you to the 14 SMC members who participated in the pilot.

Initial feedback has been positive and those members who participated in the pilot will be asked to complete an evaluation form and where possible, we will address any issues arising from this. 

From the SMC meeting in November 2011 the Secretariat will no longer send out hard copy meeting papers to members.  Members will be provided with a login and password to enable them to login into the secure site to print or download their meeting papers to their laptop for review.  The Secretariat will inform members when paperwork is available to be downloaded from the secure site.

There is no wireless internet access in Delta House so papers should be downloaded or printed in advance of the meeting.

We appreciate that not all members will wish to bring their laptop to the meeting or to print out all copies of meeting papers.  Therefore, if it would be helpful, the Secretariat could project the submissions onto a large screen in the meeting room so that specific pages can be viewed during the discussion.

We very much appreciate your co-operation in this new way of working and would be grateful for any comments you may have that you feel may make this transition easier for you.

The Chairman thanked the Secretariat for the hard work involved in establishing the secure site.

NICE Advice

8.2 Nothing to report.

9. NDC ASSESSMENT REPORTS

FULL SUBMISSIONS

9.1 ranibizumab, 10mg/mL solution for injection (Lucentis®)  Novartis Pharmaceuticals UK Ltd  SMC No. (732/11)

9.1.1 A member with a personal specific interest left the meeting for this part of the agenda.

9.1.2 The NDC Lead Assessor provided an overview of the assessment, draft advice, expert comments, revised data/analyses and comments received from the company.  A member of PAPIG presented a patient interest group submission from RNIB Scotland.  Detailed discussion followed and the group agreed that ranibizumab (Lucentis®), should be accepted for restricted use within NHS Scotland.

Indication under review: for the treatment of visual impairment due to macular oedema (MO) secondary to retinal vein occlusion (RVO) (branch RVO or central RVO) in adults.

SMC restriction: restricted to use in patients with macular oedema secondary to central retinal vein occlusion (CRVO).

Ranibizumab was associated with significant improvements in visual acuity during 6-month sham-controlled treatment in one study in patients with branch retinal vein occlusion  and in one study in patients with central retinal vein occlusion.  The benefits were considerable in patients with CRVO and there is a lack of alternative treatment options for these patients.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ranibizumab. This SMC advice is contingent upon the continuing availability of the PAS in NHS Scotland.

The submitting company did not present a sufficiently robust economic analysis for ranibizumab in the treatment of BRVO to gain acceptance by SMC.

Assessors in liaison with the Secretariat, to make appropriate amendments for review by the Chairman prior to distribution of the advice.

9.1.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011.

9.2 naproxen/esomeprazole 500mg/20mg modified release tablets (Vimovo®)  AstraZeneca UK  SMC No. (734/11)

9.2.1 Declarations of interest were recorded in relation to this product/comparator drugs.  Members with a personal specific interest left the meeting for this part of the agenda.

9.2.2 The NDC Lead Assessor provided an overview of the assessment, draft advice, expert comments, revised data/analyses and comments received from the company.  A member of PAPIG presented a patient interest group submission from Arthritis Care in Scotland. Detailed discussion followed and the group agreed that naproxen/esomeprazole (Vimovo®), should not be recommended for use within NHS Scotland.

Indication under review: the symptomatic treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS), in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.

Studies have demonstrated that combined naproxen/esomeprazole was associated with a lower incidence of endoscopic gastric ulcers than NSAID alone and similar improvements in pain and functioning compared to a cyclo-oxygenase-2 selective inhibitor.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

9.2.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011

9.3 golimumab 50mg solution for injections prefilled pen (auto-injector) or pre-filled syringe (Simponi®)  MSD Ltd  SMC No. (733/11)

9.3.1 Declarations of interest were recorded in relation to this product/comparator drugs.  A member with a personal specific interest left the meeting for this part of the agenda.

9.3.2 The NDC Lead Assessor provided an overview of the assessment, draft advice, expert comments, revised data/analyses, summary of information for patients and comments received from the company.  A member of PAPIG presented a patient interest group submission from National Rheumatoid Arthritis Society.  Detailed discussion followed and the group agreed that golimumab (Simponi®), should be accepted for restricted use within NHS Scotland.

Indication under review: In combination with methotrexate, for the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease modifying anti-rheumatic drug therapy including methotrexate has been inadequate.

Golimumab, in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.

SMC restriction:  golimumab is restricted for use in accordance with British Society for Rheumatology guidance on prescribing TNFa blockers in adults with rheumatoid arthritis (2005). Golimumab is restricted to use at a dose of 50 mg only.

There are no head to head studies comparing golimumab with other TNFa inhibitors in the treatment of rheumatoid arthritis.  Golimumab plus methotrexate was superior to methotrexate alone for the primary endpoint (ACR20 response and improvement in HAQ-DI) in patients with active rheumatoid arthritis despite methotrexate treatment.

The economic case was demonstrated for golimumab when used at a dose of 50 mg. The economic case was not demonstrated for the 100 mg dose of golimumab.

Golimumab is also licensed for use in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. SMC cannot recommend the use of golimumab in this setting, however, as the company submission related only to its use in patients with an inadequate response to methotrexate.

9.3.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011.

9.4 cabazitaxel, 60mg concentrate and solvent for solution for infusion (Jevtana®)  Sanofi-Aventin  SMC No. (735/11)

9.4.1 A member with a personal specific interest left the meeting for this part of the agenda.

9.4.2 The NDC Co-Vice Chair provided an overview of the assessment, draft advice, expert comments, and comments received from the company.  A member of PAPIG presented a patient interest group submission from The Prostate Cancer Charity Scotland. Detailed discussion followed and the group agreed that cabazitaxel (Jevtana®), should not be recommended for use within NHS Scotland.

Indication under review: In combination with prednisone or prednisolone, cabazitaxel is licensed for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

In an open-label, multicentre, randomised, controlled phase III study in patients with metastatic hormone-refractory prostate cancer, treatment with cabazitaxel plus prednisone or prednisolone was associated with an extended median overall survival of 2.4 months compared with an alternative chemotherapy regimen.

The submitting company’s justification of the treatment's cost in relation to its health benefits was not sufficient to gain acceptance by SMC.

9.4.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011.

RESUBMISSIONS

9.5 aprepitant 80mg, 125mg hard capsules (Emend®)  Merck, Sharp & Dohme Ltd  SMC No. (242/06)

9.5.1 Declarations of interest were recorded in relation to this product/comparator drugs.  A member with a personal specific interest left the meeting for this part of the agenda.

9.5.2 The NDC Lead Assessor provided an overview of the assessment, draft advice, expert comments, and comments received from the company.  Detailed discussion followed and the group agreed that aprepitant (Emend®), should not be recommended for use within NHS Scotland.

Indication under review: As part of combination therapy, for prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.  Compared with a control regimen, aprepitant has been shown to increase the proportion of patients achieving a complete response in a study of breast cancer patients or experiencing no vomiting in patients with a range of tumour types, when patients were initiated on their first cycle of a moderately emetogenic chemotherapy regimen. However the control regimen was considered suboptimal for the treatment of delayed symptoms and evidence for use in subsequent cycles is limited.

Overall the submitting company did not present sufficiently robust clinical and economic analyses to gain acceptance by SMC.

9.5.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011.

9.6 paliperidone palmitate 50mg, 75mg, 100mg and 150mg prolonged release suspension for injection (Xeplion) Janssen-Cilag Ltd  SMC No. (713/11)

9.6.1 There were no declarations on interest recorded in relation to this product/comparator drugs.
 
9.6.2 The NDC Co-Vice Chair provided an overview of the assessment, draft advice, expert comments, revised data/analyses and comments received from the company.  A member of PAPIG presented patient interest group submissions from SANE.  Detailed discussion followed and the group agreed that paliperidone palmitate (Xeplion), should be accepted for use within NHS Scotland.

Indication under review: maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.  In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.

Paliperidone prolonged release suspension for injection was non-inferior to another atypical antipsychotic depot injection in terms of control of schizophrenia symptoms over a 3-month period and was more effective than placebo in preventing relapse of schizophrenia.

9.6.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011.

ABBREVIATED SUBMISSIONS

9.7 fluticasone proprionate and formoterol fumarate metered dose inhaler, 50microgram/5microgram, 125microgram/5 microgram 250microgram/10 microgram (Flutiform®)  Napp Pharmaceuticals Ltd  SMC No. (736/11)

9.7.1 There were no declarations on interest recorded in relation to this product/comparator drugs.
 
9.7.2 The NDC Co-Vice Chair provided an overview of the assessment and draft advice.  Detailed discussion followed and the group concluded their advice for fluticasone proprionate and formoterol fumarate metered dose inhaler (Flutiform®).

Indication under review: in the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting ß2 agonist (LABA)] is appropriate:

  • for patients not adequately controlled on ICS and ‘as required’ inhaled short-acting ß2 agonist or;
  • for patients already adequately controlled on both an ICS and a LABA.

Flutiform® should be used in patients for whom fluticasone and formoterol are appropriate choices of corticosteroid and long-acting beta-agonist, respectively, and for whom a metered dose inhaler is an appropriate delivery device. It has costs similar to another combination product containing a corticosteroid and long-acting beta2-agonist to which it has demonstrated clinical non-inferiority.

9.7.3 The SMC advice will be withheld pending confirmation of the licence and product availability.

9.8 somatropin 5.83mg/ml and 8mg/ml solution for injection (Saizen®)  Merck Serono Ltd  SMC No. (737/11)
 
9.8.1 There were no declarations of interest recorded in relation to this product/comparator drugs.

9.8.2 The NDC Co-Vice Chair provided an overview of the assessment and draft advice.  Detailed discussion followed and the group agreed that somatropin solution for injection (Saizen®), should be accepted for use in NHS Scotland.

Indication under review:
Children and adolescents:
- Growth failure in children caused by decreased or absent secretion of endogenous growth hormone.
- Growth failure in girls with gonadal dysgenesis (Turner Syndrome), confirmed by chromosomal analysis.
- Growth failure in prepubertal children due to chronic renal failure (CRF).
- Growth disturbance (current height SDS <-2.5 and parental adjusted height SDS <-1) in short children born small for gestational age (SGA) with a birth weight and/or length below -2 SD, who failed to show catch-up growth (HV SDS <0 during the last year) by 4 years of age or later.

Adults:
- Replacement therapy in adults with pronounced growth hormone deficiency as diagnosed by a single dynamic test for growth hormone deficiency. Patients must also fulfil the following criteria:

- Childhood Onset:
Patients who were diagnosed as growth hormone deficient during childhood, must be retested and their growth hormone deficiency confirmed before replacement therapy with Saizen is started.

- Adult Onset:
Patients must have growth hormone deficiency as a result of hypothalamic or pituitary disease and at least one other hormone deficiency diagnosed (except for prolactin) and adequate replacement therapy instituted, before replacement therapy using growth hormone may begin.

This new formulation has been shown to be bioequivalent to the previously available freeze-dried formulation and is available at an equivalent cost. It is in a ready to use cartridge and does not require reconstitution.

9.8.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011.

9.9 adalimumab (Humira®), 40mg solution for injection in pre-filled syringe or pen, 40mg/0.8ml solution for injection vial for paediatric use  Abbott Laboratories  SMC No (738/11)

9.9.1 There were no declarations on interest recorded in relation to this product/comparator drugs.
 
9.9.2 The NDC Co-Vice Chair provided an overview of the assessment and draft advice.  Detailed discussion followed and the group agreed that adalimumab (Humira®) solution for injection, should be accepted for restricted use within NHS Scotland.

Indication under review: in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.  Adalimumab has not been studied in children aged less than 4 years.

It should be restricted to use within specialist rheumatology services (including those working within the network for paediatric rheumatology). Combination treatment with methotrexate is the primary option. Doses in this age group are based on body surface area calculations.

The Scottish Medicines Consortium has previously accepted this product for restricted use for this indication in adolescents aged 13 to 17 years and for rheumatoid arthritis in adults.

9.9.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011.

9.10 abatacept (Orencia®), 250mg powder for concentrate for solution for injection  Bristol-Myers Squibb Pharmaceuticals Ltd SMC No. (618/10)

9.10.1 There were no declarations on interest recorded in relation to this product/comparator drugs. 

9.10.2 The NDC Co-Vice Chair provided an overview of the assessment and draft advice.  Detailed discussion followed and the group agreed that abatacept (Orencia®) powder for solution for injection, should be accepted for restricted use within NHS Scotland.

Indication under review: in combination with methotrexate, abatacept is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other disease modifying antirheumatic drugs (DMARDs) including at least one tumour necrosis factor (TNF) inhibitor.  It has not been studied in children under 6 years old.

It should be restricted to use within specialist rheumatology services (including those working within the network for paediatric rheumatology).  Abatacept is an anti-rheumatic agent that prevents T-lymphocyte activation.

Abatacept in combination with methotrexate has been accepted for restricted use in adults with severe active rheumatoid arthritis in line with the recommendations of the NICE Multiple Technology Appraisal no 195.  NHS Quality Improvement Scotland advised that these recommendations were valid for NHS Scotland.

9.10.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 07 October 2011.

10. SMC User Group Forum

10.1 Update from UGF Meeting

Dr Frances Macdonald advised there was only one item to follow up on in relation to the SMC Training Day and expressed thanks to SMC and PAPIG for all their contributions to a successful event.  This was well attended by industry in Scotland and feedback received from the audience was this was very informative and useful.

The Chairman agreed this was a very useful day and would like to also thank all who participated in this event.

11. Forthcoming Submissions

11.1 A list of forthcoming submissions was tabled and noted. 

12. Area Drug & Therapeutics Committee (ADTC) Issues

12.1 Professor Scott Bryson welcomed the SMC Forward Look 7 report which will be available later in October 2011.  It would be appreciated if an earlier publication date could be requested for 2012, possibly release of a month earlier as this would assist with our projections for 2013.  Mrs Anne Lee will be attending a policy group meeting in December and will discuss this request.  There have been particular challenges in 2011, the  development of UK PharmaScan has proved challenging and the database has only been populated gradually over the last year. Consideration will be given to the most appropriate publication date and the feasibility of obtaining this data from UK Pharmascan and manufacturers at the correct time.

Mrs Margo McGurk advised that the Directors of Finance are meeting in December with the SMC chair and acting chief pharmacist. It may be useful to do one piece of work mid-year to measure in terms of projection from previous year.  Mrs Anne Lee advised that the purpose of evaluation work is linked to this and it may be appropriate to await the output from this evaluation. 

13. Any Other Business

13.1 No other business was noted.

14. Date of the Next Meeting

14.1 The date of the next meeting was confirmed as Tuesday, 01 November 2011 at 12.30 pm (lunch from 12 noon), in Healthcare Improvement Scotland (Glasgow Office), Delta House, 50 West Nile Street, Glasgow G1 2NP.


NICE Publications

Minutes of the SMC Meeting 04 October 2011

There were no NICE publications reported at the SMC meeting of 04 October 2011.